CD4 and AIDS: In three recent randomized controlled trials, initiation of ART within 30 days of anti-tuberculosis therapy was associated with a decreased risk of AIDS and death, but only among persons with baseline CD4+ lymphocytes < 50 cells/mm3; the risk of disease progression and death tended to be increased among persons with higher CD4 counts [5,6,7].